
    
      Under the PB-102-F01 study protocol, patients will be enrolled into one of three PRX-102
      dosing groups (0.2 mg/kg, 1.0 mg/kg, 2.0 mg/kg) and receive PRX-102 as an intravenous
      infusion every 2 weeks for 12 weeks (3 months). Patients who finish the PB-102-F01 study will
      be enrolled in the PB-102-F02 extension study and receive the same dose they had received in
      the PB-102-F01 study for an additional 38 weeks (9 months).
    
  